Dreyling, M. Et Al. 2020. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.. American journal of hematology , vol.95, no.4 , 362-371.

Dreyling, M., Santoro, A., Mollica, L., Leppae, S., Follows, G., Lenz, G., ... Kim, W. S.(2020). Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.. American journal of hematology , vol.95, no.4, 362-371.

Dreyling, Martin Et Al. "Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.," American journal of hematology , vol.95, no.4, 362-371, 2020

Dreyling, Martin Et Al. "Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.." American journal of hematology , vol.95, no.4, pp.362-371, 2020

Dreyling, M. Et Al. (2020) . "Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.." American journal of hematology , vol.95, no.4, pp.362-371.

@article{article, author={Martin Dreyling Et Al. }, title={Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.}, journal={American journal of hematology}, year=2020, pages={362-371} }